

Subject index

Volume 36 (1997)

-
- Acanthospermum hispidum***; Alphaherpesviruses; Inhibition of adsorption **36**, 55
- Adefovir dipivoxil**; PMEA; PMPA; HIV; Drug combinations **36**, 91
- Adefovir**; PMEA; HCMV; Antiviral **36**, 131
- Age-dependent poliomyelitis**; Lactate dehydrogenase-elevating virus; Interferon- γ **36**, 1
- Alkoxy propane**; Prodrugs; Foscarnet; HIV-1; HSV-1; HCMV **36**, 43
- Alphaherpesviruses**; *Acanthospermum hispidum*; Inhibition of adsorption **36**, 55
- Antioxidant**; Topical therapy; Herpes **36**, 157
- Antiviral activity**; *Centaurea rupestris* L.; Flavonoid; Plant virus **36**, 125
- Antiviral agents**; Cytomegalovirus; Lipids; Prodrugs; Structure–activity relationship **36**, 115
- Antiviral compounds**; Prostaglandins; Triterpenes; Glycyrrhizic acid; Carbenoxolone **36**, 191
- Antiviral drug**; HSV-1; Protein kinase; US3 PK; D609; Protein phosphorylation **36**, 63
- Antiviral drugs**; HIV-1; Resistance; Homologous recombination **36**, 179
- Antiviral**; PMEA; Adefovir; HCMV **36**, 131
- Antiviral therapy**; HIV-1; In vivo model; SCID mice **36**, 81
- Antiviral toxicity**; 9-[(2*R*,5*R*-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine; Feline immunodeficiency virus **36**, 11
- Bestatin**; Human immunodeficiency virus; Leucine aminopeptidase; Protein kinase C; Viral entry **36**, 167
- Carbenoxolone**; Antiviral compounds; Prostaglandins; Triterpenes; Glycyrrhizic acid **36**, 191
- Centaurea rupestris* L.**; Flavonoid; Antiviral activity; Plant virus **36**, 125
- 3' cleavage activity assay**; HIV-1; Integrase inhibition **36**, 27
- Cytomegalovirus**; Antiviral agents; Lipids; Prodrugs; Structure–activity relationship **36**, 115
- D609**; HSV-1; Protein kinase; US3 PK; Antiviral drug; Protein phosphorylation **36**, 63
- Drug combinations**; Adefovir dipivoxil; PMEA; PMPA; HIV **36**, 91
- Emerging viruses**; Virus evolution; Host modification; PCR; Vector population **36**, 75
- Feline immunodeficiency virus**; 9-[(2*R*,5*R*-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine; Antiviral toxicity **36**, 11
- Flavonoid**; *Centaurea rupestris* L.; Antiviral activity; Plant virus **36**, 125
- Foscarnet**; Alkoxy propane; Prodrugs; HIV-1; HSV-1; HCMV **36**, 43
- Glycyrrhizic acid**; Antiviral compounds; Prostaglandins; Triterpenes; Carbenoxolone **36**, 191
- HCMV**; Alkoxy propane; Prodrugs; Foscarnet; HIV-1; HSV-1 **36**, 43

- HCMV**; PMEA; Adefovir; Antiviral 36, 131
- Herpes**; Antioxidant; Topical therapy 36, 157
- Herpes simplex virus**; Herpetic stromal keratitis; Immunopathology; Interferon; Interleukin-10 36, 99
- Herpetic stromal keratitis**; Herpes simplex virus; Immunopathology; Interferon; Interleukin-10 36, 99
- HIV**; Adefovir dipivoxil; PMEA; PMPA; Drug combinations 36, 91
- HIV-1**; Alkoxy propane; Prodrugs; Foscarnet; HSV-1; HCMV 36, 43
- HIV-1**; Integrase inhibition; 3' cleavage activity assay 36, 27
- HIV-1**; In vivo model; SCID mice; Antiviral therapy 36, 81
- HIV-1**; Resistance; Antiviral drugs; Homologous recombination 36, 179
- Homologous recombination**; HIV-1; Resistance; Antiviral drugs 36, 179
- Host modification**; Emerging viruses; Virus evolution; PCR; Vector population 36, 75
- HSV-1**; Alkoxy propane; Prodrugs; Foscarnet; HIV-1; HCMV 36, 43
- HSV-1**; Protein kinase; US3 PK; Antiviral drug; D609; Protein phosphorylation 36, 63
- Human immunodeficiency virus**; Bestatin; Leucine aminopeptidase; Protein kinase C; Viral entry 36, 167
- Human immunodeficiency virus type 1**; Protease inhibitors; Proviral DNA 36, 107
- Immunopathology**; Herpes simplex virus; Herpetic stromal keratitis; Interferon; Interleukin-10 36, 99
- Inhibition of adsorption**; *Acanthospermum hispidum*; Alphaherpesviruses 36, 55
- Integrase inhibition**; HIV-1; 3' cleavage activity assay 36, 27
- Integrase**; Retrovirus; Integration 36, 139
- Integration**; Retrovirus; Integrase 36, 139
- Interferon- γ** ; Age-dependent poliomyelitis; Lactate dehydrogenase-elevating virus 36, 1
- Interferon**; Herpes simplex virus; Herpetic stromal keratitis; Immunopathology; Interleukin-10 36, 99
- Interleukin-10**; Herpes simplex virus; Herpetic stromal keratitis; Immunopathology; Interferon 36, 99
- In vivo model**; HIV-1; SCID mice; Antiviral therapy 36, 81
- Lactate dehydrogenase-elevating virus**; Age-dependent poliomyelitis; Interferon- γ 36, 1
- Leucine aminopeptidase**; Human immunodeficiency virus; Bestatin; Protein kinase C; Viral entry 36, 167
- Lipids**; Antiviral agents; Cytomegalovirus; Prodrugs; Structure-activity relationship 36, 115
- Nucleoside analogs**; Phosphorylation UL97; Recombinant vaccinia viruses 36, 35
- PCR**; Emerging viruses; Virus evolution; Host modification; Vector population 36, 75
- Phosphorylation UL97**; Recombinant vaccinia viruses; Nucleoside analogs 36, 35
- Plant virus**; *Centaurea rupestris* L.; Flavonoid; Antiviral activity 36, 125
- PMEA**; Adefovir dipivoxil; PMPA; HIV; Drug combinations 36, 91
- PMEA**; Adefovir; HCMV; Antiviral 36, 131
- PMPA**; Adefovir dipivoxil; PMEA; HIV; Drug combinations 36, 91
- Prodrugs**; Alkoxy propane; Foscarnet; HIV-1; HSV-1; HCMV 36, 43
- Prodrugs**; Antiviral agents; Cytomegalovirus; Lipids; Structure-activity relationship 36, 115
- Prostaglandins**; Antiviral compounds; Triterpenes; Glycyrrhizic acid; Carbenoxolone 36, 191
- Protease inhibitors**; Human immunodeficiency virus type 1; Proviral DNA 36, 107
- Protein kinase C**; Human immunodeficiency virus; Bestatin; Leucine aminopeptidase; Viral entry 36, 167
- Protein kinase**; HSV-1; US3 PK; Antiviral drug; D609; Protein phosphorylation 36, 63
- Protein phosphorylation**; HSV-1; Protein kinase; US3 PK; Antiviral drug; D609 36, 63

Proviral DNA; Human immunodeficiency virus type 1; Protease inhibitors **36**, 107

Recombinant vaccinia viruses; Phosphorylation UL97; Nucleoside analogs **36**, 35

Resistance; HIV-1; Antiviral drugs; Homologous recombination **36**, 179

Retrovirus; Integrase; Integration **36**, 139

9-[(2*R*,5*R*-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine; Feline immunodeficiency virus; Antiviral toxicity **36**, 11

SCID mice; HIV-1; In vivo model; Antiviral therapy **36**, 81

Structure–activity relationship; Antiviral agents; Cytomegalovirus; Lipids; Prodrugs **36**, 115

Topical therapy; Antioxidant; Herpes **36**, 157

Triterpenes; Antiviral compounds; Prostaglandins; Glycyrrhizic acid; Carbenoxolone **36**, 191

US3 PK; HSV-1; Protein kinase; Antiviral drug; D609; Protein phosphorylation **36**, 63

Vector population; Emerging viruses; Virus evolution; Host modification; PCR **36**, 75

Viral entry; Human immunodeficiency virus; Bestatin; Leucine aminopeptidase; Protein kinase C **36**, 167

Virus evolution; Emerging viruses; Host modification; PCR; Vector population **36**, 75